Kolexia
Pautas Cecile Hématologie
Pautas Cecile
Hématologie
Hôpital Henri Mondor
Créteil, France
145 Activités
3 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie aigüe myéloïde Leucémie myéloïde Maladie résiduelle Mycoses Lymphomes Neutropénie Syndromes myélodysplasiques Neutropénie fébrile

Collaborateurs

Voir plus
Dombret Herve
Dombret Herve
Hôpital Saint-Louis, Paris, France
Raffoux Emmanuel
Raffoux Emmanuel
Hôpital Saint-Louis, Paris, France
Thomas Xavier
Thomas Xavier
Hôpital Lyon Sud, Pierre-Bénite, France
Preudhomme Claude
Preudhomme Claude
Hôpital Albert Calmette, Lille, France

Industries

Voir plus
Abbvie
6 collaboration(s)
Dernière en 2023
Celgene
4 collaboration(s)
Dernière en 2021
Astellas
3 collaboration(s)
Dernière en 2021
Pfizer
3 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
OGILAR: Open-label, Phase 2 Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia
Essai Clinique (French Innovative Leukemia Organisation)   05 février 2024
ALFA2101: An ALFA 2101 Multicenter Randomized Phase II Study: CPX-351 Versus Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
Essai Clinique (CHU Nice)   29 janvier 2024
Prognostic impact of CEBPA mutational subgroups in adult AML.
Leukemia   16 janvier 2024
Long-term outcome after autologous BCR::ABL1-negative peripheral blood stem cell transplantation in adults with Philadelphia-positive acute lymphoblastic leukemia: a comparative study.
Haematologica   30 novembre 2023
AGORA-1 /ALFA 2100 Study : A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD Relapse/Refractory (R/R) AML
Essai Clinique (Centre Antoine Lacassagne)   09 novembre 2023
Current Results of Intensive Therapy in Younger Adults with Acute Myeloid Leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 Study on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
65th ASH Annual Meeting Abstracts   02 novembre 2023
Gemtuzumab Ozogamicin for Patients with Newly Diagnosed CD33 Positive Acute Myeloid Leukemia: Results from a French Retrospective Observational Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
Venetoclax in Combination with Intermediate Doses of Cytarabine in Consolidation Phase for Acute Myeloid Leukemia Patients in First Complete Remission; Results of the Part 1 of the Phase 1/2 Multicentric Covenidac Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
Mutational Profile and Dynamics of PPM1D-Mutant Clones in the Spectrum of Myeloid Disorders
65th ASH Annual Meeting Abstracts   02 novembre 2023
Hyperleukocytosis Increases the Risk of Early Relapses Independently of Genetics in AML
65th ASH Annual Meeting Abstracts   02 novembre 2023